We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Q32 Bio Gears Up to Report Q1 Earnings: What's in the Cards?
Read MoreHide Full Article
Key Takeaways
QTTB is unlikely to report any product revenues. Consensus sees a 52 cents per share Q1 loss.
SIGNAL-AA part B study enrollment is complete. Top-line bempikibart data is due in mid-2026.
Q32 Bio sold ADX-097 to AKBA, as payments are expected to extend the cash runway into Q4 2027.
We expect investors to focus on updates related to Q32 Bio’s (QTTB - Free Report) pipeline development when it reports first-quarter 2026 earnings.
Since the company lacks a marketed drug in its portfolio, no revenues are expected to have been recorded from product sales in the first quarter of 2026. The Zacks Consensus Estimate for the first-quarter bottom line is pegged at a loss of 52 cents per share.
Factors Shaping QTTB’s Upcoming Results
With no approved/marketed product in its portfolio, investor focus on Q32 Bio’s earnings call is likely to be on updates related to its most advanced product candidate, bempikibart (ADX-914), a fully human anti-IL-7Rα antibody, which is being developed for treating alopecia areata (“AA”).
The company recently completed enrollment in part B of the phase IIa SIGNAL-AA study, which is evaluating bempikibart in patients with severe or very severe AA. Patients in the study will receive bempikibart for 36 weeks, with follow-up out to 52 weeks.
Top-line data from the study is expected to be announced in mid-2026. Investors will be keen to get more updates on the same on the first-quarter earnings call.
The FDA previously granted Fast Track designation to bempikibart for the treatment of AA.
Year to date, shares of Q32 Bio have surged 65.6% against the industry’s 1.5% decline.
Image Source: Zacks Investment Research
In December 2025, Q32 Bio sold its phase II complement inhibitor, ADX-097, to Akebia Therapeutics (AKBA - Free Report) . This deal with AKBA looks like a strategic fit for Q32 Bio, as it is likely to help the latter focus on advancing bempikibart for AA and fund pipeline development activities.
Per the deal, Q32 Bio is eligible to receive up to a total of $592 million as potential milestone payments, including an upfront payment of $12 million from Akebia. This is likely to fund QTTB’s operations into the fourth quarter of 2027.
Operating expenses are likely to have declined in the to-be-reported quarter, reflecting lower costs related to clinical studies and other expenses.
QTTB’s Earnings Surprise History
Q32 Bio has an encouraging history of earnings surprises. The company beat on earnings in each of the trailing three quarters, delivering an average surprise of 205.94%. In the last reported quarter, QTTB delivered an earnings surprise of 529.41%.
Our proven model does not conclusively predict an earnings beat for Q32 Bio this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Q32 Bio has an Earnings ESP of 0.00%.
Here are some stocks worth considering from the healthcare space, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
Agenus (AGEN - Free Report) has an Earnings ESP of +7.69% and a Zacks Rank #1 at present.
Shares of AGEN have risen 22.3% year to date. The company’s earnings beat estimates in two of the trailing four quarters, while missing the mark on the other two occasions. Agenus delivered an average earnings surprise of 31.42%.
Inovio Pharmaceuticals (INO - Free Report) has an Earnings ESP of +3.33% and a Zacks Rank #2 at present.
Shares of INO have lost 35.7% year to date. The company’s earnings beat estimates in each of the trailing four quarters. INO delivered an average earnings surprise of 57.94%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Q32 Bio Gears Up to Report Q1 Earnings: What's in the Cards?
Key Takeaways
We expect investors to focus on updates related to Q32 Bio’s (QTTB - Free Report) pipeline development when it reports first-quarter 2026 earnings.
Since the company lacks a marketed drug in its portfolio, no revenues are expected to have been recorded from product sales in the first quarter of 2026. The Zacks Consensus Estimate for the first-quarter bottom line is pegged at a loss of 52 cents per share.
Factors Shaping QTTB’s Upcoming Results
With no approved/marketed product in its portfolio, investor focus on Q32 Bio’s earnings call is likely to be on updates related to its most advanced product candidate, bempikibart (ADX-914), a fully human anti-IL-7Rα antibody, which is being developed for treating alopecia areata (“AA”).
The company recently completed enrollment in part B of the phase IIa SIGNAL-AA study, which is evaluating bempikibart in patients with severe or very severe AA. Patients in the study will receive bempikibart for 36 weeks, with follow-up out to 52 weeks.
Top-line data from the study is expected to be announced in mid-2026. Investors will be keen to get more updates on the same on the first-quarter earnings call.
The FDA previously granted Fast Track designation to bempikibart for the treatment of AA.
Year to date, shares of Q32 Bio have surged 65.6% against the industry’s 1.5% decline.
Image Source: Zacks Investment Research
In December 2025, Q32 Bio sold its phase II complement inhibitor, ADX-097, to Akebia Therapeutics (AKBA - Free Report) . This deal with AKBA looks like a strategic fit for Q32 Bio, as it is likely to help the latter focus on advancing bempikibart for AA and fund pipeline development activities.
Per the deal, Q32 Bio is eligible to receive up to a total of $592 million as potential milestone payments, including an upfront payment of $12 million from Akebia. This is likely to fund QTTB’s operations into the fourth quarter of 2027.
Operating expenses are likely to have declined in the to-be-reported quarter, reflecting lower costs related to clinical studies and other expenses.
QTTB’s Earnings Surprise History
Q32 Bio has an encouraging history of earnings surprises. The company beat on earnings in each of the trailing three quarters, delivering an average surprise of 205.94%. In the last reported quarter, QTTB delivered an earnings surprise of 529.41%.
Q32 Bio Inc. Price and EPS Surprise
Q32 Bio Inc. price-eps-surprise | Q32 Bio Inc. Quote
What Our Model Predicts for QTTB
Our proven model does not conclusively predict an earnings beat for Q32 Bio this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Q32 Bio has an Earnings ESP of 0.00%.
Zacks Rank: QTTB currently sports a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks to Consider
Here are some stocks worth considering from the healthcare space, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
Agenus (AGEN - Free Report) has an Earnings ESP of +7.69% and a Zacks Rank #1 at present.
Shares of AGEN have risen 22.3% year to date. The company’s earnings beat estimates in two of the trailing four quarters, while missing the mark on the other two occasions. Agenus delivered an average earnings surprise of 31.42%.
Inovio Pharmaceuticals (INO - Free Report) has an Earnings ESP of +3.33% and a Zacks Rank #2 at present.
Shares of INO have lost 35.7% year to date. The company’s earnings beat estimates in each of the trailing four quarters. INO delivered an average earnings surprise of 57.94%.